Amphastar Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: David Gaugh

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David Gaugh”): 35,242,863 for, 209,084 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 14,165,044 for, 6,096 against, 13,430 abstained.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

Description as filed by funds: To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Jacob Liawatidewi

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacob Liawatidewi”): 23,224,791 for, 12,212,988 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 66% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 7,819,667 for, 6,351,473 against, 13,430 abstained.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

Description as filed by funds: To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: William J. Peters

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William J. Peters”): 23,652,131 for, 11,785,772 against, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 8,139,524 for, 6,031,616 against, 13,430 abstained.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers; and”): 32,585,908 for, 2,779,281 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 79 managers: 12,621,689 for, 1,541,450 against, 21,430 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 200 managers: 9,869,201 for, 2,032,395 against, 10,600 abstained, 425 not voted, 37,533 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the frequency of future stockholder advisory votes on our named executive officer compensation.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 77 managers: 35,637 for, 13,430 abstained, 13,394,870 1 year, 698,819 3 year, 8,184 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 195 managers: 36,919 for, 1,214 against, 10,600 abstained, 425 not voted, 11,567,443 1 year, 184,987 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026; and

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 39,179,786 for, 684,828 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 13,995,431 for, 175,709 against, 13,430 abstained.

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.